Sorafenib for the treatment of unresectable hepatocellular carcinoma

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 779-788

  Furuse, Junji ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Platelet derived growth factor receptor; Raf kinase; Sorafenib; Vascular endothelial growth factor receptor

Indexed keywords

EID: 77956824960     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3410     Document Type: Review

References (51)

1. Abou-Alfa G, Johnson P, Knox J, et al. 2008b. Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer, 5(Suppl):259, #3500.
2. Abou-Alfa GK, Amadori D, Santoro A, et al. 2008a. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? Proc Am Soc Clin Oncol, 26:217s, #4518.
3. Abou-Alfa GK, Schwartz L, Ricci S, et al. 2006. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24:4293-300.
4. Avila MA, Berasain C, Sangro B, et al. 2006. New therapies for hepatocellular carcinoma. Oncogene, 25:3866-84.
5. Boucher E, Corbinais S, Brissot P, et al. 2002. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol, 50:305-8.
6. Bruix J, Sherman M, Llovet JM, et al. 2001. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35:421-30.
7. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology, 42:1208-36.
8. Chang YS, Adnane J, Trail PA, et al. 2007. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol, 59:561-74.
9. Chao Y, Li CP, Chau GY, et al. 2003. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol, 10:355-62.
10. Chen J, Siddiqui A. 2007. Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. J Virol, 81:6757-60.
11. Cheng AL, Kang Y, Chen Z, et al. 2008. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol, 26:215s, #4509.
12. Colleoni M, Nole F, Di Bartolomeo M, et al. 1992. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology, 49:139-42.
13. Davies H, Bignell GR, Cox C, et al. 2002. Mutations of the BRAF gene in human cancer. Nature, 417:949-54.
14. El-Serag HB, Mason AC. 1999. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 340:745-50.
15. Faivre SJ, Raymond E, Douillard J, et al. 2007. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol, 25:149s, #3546.
16. Furuse J, Ishii H, Nakachi K, et al. 2008. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci, 99:159-65.
17. Giambartolomei S, Covone F, Levrero M, et al. 2001. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene, 20:2606-10.
18. Gollob JA, Wilhelm S, Carter C, et al. 2006. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol, 33:392-406.
19. Hackel PO, Zwick E, Prenzel N, et al. 1999. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol, 11:184-9.
20. Hood JD, Bednarski M, Frausto R, et al. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science, 296:2404-7.
21. Huynh H, Nguyen TT, Chow KH, et al. 2003. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol, 3:19-39.
22. Hwang YH, Choi JY, Kim S, et al. 2004. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res, 29:113-21.
23. Ikai I, Arii S, Ichida T, Okita K, et al. 2005. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res, 32:163-72.
24. Ikeda M, Okusaka T, Ueno H, et al. 2005. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer, 103:756-62.
25. Ito Y, Sasaki Y, Horimoto M, et al. 1998. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology, 27:951-8.
26. Kimura ET, Nikiforova MN, Zhu Z, et al. 2003. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63:1454-7.
27. Kudo M, Okanoue T; Japan Society of Hepatology. 2007. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology, 72(Suppl 1):2-15.
28. Lai CL, Wu PC, Chan GC, et al. 1988. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer, 62:479-83.
29. Leung TW, Patt YZ, Lau WY, et al. 1999. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res, 5:1676-81.
30. Liu L, Cao Y, Chen C, Zhang X, et al. 2006. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 66:11851-8.
31. Llovet JM, Ricci S, Mazzaferro V, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359:378-90.
32. McGlynn KA, Tsao L, Hsing AW, et al. 2001. International trends and patterns of primary liver cancer. Int J Cancer, 94:290-6.
33. Miller AA, Murry DJ, Owzar K, et al. 2007. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. Proc Am Soc Clin Oncol, 25:147s, #3538.
34. Miura H, Miyazaki T, Kuroda M, et al. 1997. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol, 27:854-61.
35. Oka H, Chatani Y, Hoshino R, et al. 1995. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res, 55:4182-7.
36. Parkin DM, Bray F, Ferlay J, et al. 2005. Global cancer statistics, 2002. CA Cancer J Clin, 55:74-108.
37. Patt YZ, Hassan MM, Lozano RD, et al. 2003. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol, 21:421-7.
38. Poon RT, Ho JW, Tong CS, et al. 2004. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg, 91:1354-60.
39. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. 1973. Transection of the esophagus for bleeding esophageal varices. Br J Surg, 60:646-54.
40. Schmidt CM, McKillop IH, Cahill PA, et al. 1997. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun, 236:54-8.
41. Siegel AB, Cohen EI, Ocean A, et al. 2008. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol, 26:2992-8.
42. Stranger BE, Nica AC, Forrest MS, et al. 2007. Population genomics of human gene expression. Nat Genet, 39:1217-24.
43. Strumberg D, Richly H, Hilger RA, et al. 2005. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23:965-72.
44. Thomas MB, Chadha R, Iwasaki M, et al. 2007. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol, 25:214s, #4567.
45. Wilhelm S, Carter C, Lynch M, et al. 2006. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5:835-44.
46. Wilhelm SM, Carter C, Tang L, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64:7099-109.
47. Woodburn JR. 1999. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther, 82:241.
48. Yamaguchi R, Yano H, Iemura A, et al. 1998. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 28:68-77.
49. Yeo W, Mok TS, Zee B, et al. 2005. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst, 97:1532-8.
50. Zhang W, Duan S, Kistner EO, et al. 2008. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet, 82:631-40.
51. Zhu AX, Sahani DV, di Tomaso E, et al. 2008. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. Proc Am Soc Clin Oncol, 26:218s, #4521.